DRUG INTERACTION

Contraindicated  

Serious Use Alternative  

Monitor Closely  

Minor  

Frequency defined:  

>10% 

Urinary tract infection 

Elevated BP 

1-10% 

Children 

Cough 

Nausea 

Rhinitis 

Constipation 

Headache 

Nasopharyngitis 

Gastroenteritis 

Adults 

Monotherapy 

Arthralgia 

Headache 

Dizziness 

Diarrhea 

Fatigue 

Constipation 

Dry mouth 

Sinusitis 

Urinary tract infection 

Combined with solifenacin 

Arthralgia 

Dizziness 

Constipation 

Dry mouth 

Dyspepsia 

Blurred vision 

UTI 

Tachycardia 

<1% 

Rhinitis 

Glaucoma 

Palpitation 

Bladder pain 

Urticaria 

Lip edema 

Rash 

Elevated blood pressure 

Gastritis 

Post-marketing reports 

Constipation 

Nausea 

Atrial fibrillation 

Angioedema 

Dizziness 

Urinary retention 

pruritus 

Pregnancy consideration: Insufficient data available 

Lactation: The excretion of the drug is unknown 

 

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh the risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: No data is available for the drug under this category. 

Patient information leaflet 

Generic Name: mirabegron 

Pronounced: mye-ra-beg-ron 

Why do we use mirabegron? 

It is used to treat neurogenic detrusor overactivity and overactive bladder